Weiss, Jennifer M.
Kim, David H.
Smith, Maureen A.
Potvien, Aaron
Schumacher, Jessica R.
Gangnon, Ronald E.
Pooler, B. Dustin
Pfau, Patrick R.
Pickhardt, Perry J.
Funding for this research was provided by:
National Cancer Institute (R01 CA144835, P30 CA014520, R01 CA144835)
American Cancer Society (MRSG-13-144-01-CPHPS)
National Center for Advancing Translational Sciences (UL1TR000427)
Article History
First Online: 19 November 2016
Compliance with ethical standards
:
: This work was supported by the National Cancer Institute (Grants R01 CA144835 and P30 CA014520); the National Center for Advancing Translational Sciences (Grant UL1TR000427); the American Cancer Society (Grant MRSG-13-144-01-CPHPS); and the UW Health Innovation Program.
: Perry J. Pickhardt is co-founder of VirtuoCTC and shareholder in SHINE, Elucent, and Cellectar Biosciences. David H. Kim is co-founder of VirtuoCTC, consultant for Viatronix, on the Medical Advisory Board for Digital ArtForms, and shareholder in Cellectar and Elucent. Patrick R. Pfau serves on the Scientific Advisory Board of Exact Sciences. The other authors declare that they have no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.
: Statement of informed consent was not applicable since the manuscript does not contain any patient data.